Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
0.8661
-0.0310 (-3.46%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Werewolf Therapeutics Stock Forecast
HOWL's stock price has decreased by -86.45% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Werewolf Therapeutics stock have an average target of 9.00, with a low estimate of 4.00 and a high estimate of 15. The average target predicts an increase of 939.14% from the current stock price of 0.87.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 12, 2025.
Analyst Ratings
The average analyst rating for Werewolf Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +823.68% | Mar 12, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,631.90% | Mar 12, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $12 → $4 | Buy | Maintains | $12 → $4 | +361.84% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,631.90% | Nov 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +1,631.90% | Jul 2, 2024 |
Financial Forecast
Revenue This Year
1.22M
from 1.89M
Decreased by -35.07%
Revenue Next Year
10.20M
from 1.22M
Increased by 733.33%
EPS This Year
-1.80
from -1.63
EPS Next Year
-1.54
from -1.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.3M | 52.5M | 24.4M | ||
| Avg | 1.2M | 10.2M | 5.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 234.2% | 4,189.2% | 138.8% | ||
| Avg | -35.1% | 733.3% | -42.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.73 | -0.85 | -1.63 | ||
| Avg | -1.80 | -1.54 | -1.71 | ||
| Low | -1.86 | -2.20 | -1.98 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.